Close Menu

NEW YORK – Oppenheimer on Wednesday initiated coverage of Fulgent Genetics with an Outperform rating and a price target on its shares of $75.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.